What is the recommended treatment for panic disorder?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment for Panic Disorder

Start with an SSRI (selective serotonin reuptake inhibitor) or SNRI (serotonin-norepinephrine reuptake inhibitor) combined with cognitive behavioral therapy (CBT) for optimal outcomes in panic disorder. 1

First-Line Treatment Approach

The evidence strongly supports a dual-modality strategy:

Pharmacotherapy

  • SSRIs are the gold standard first-line medication 1, 2, 3, 4, 5

    • Examples include paroxetine, sertraline, escitalopram
    • Paroxetine titrated up to 60 mg/day showed significantly greater reduction in panic symptoms compared to continued CBT alone 6
    • Sertraline mean effective dose was 180 mg/day 6
  • SNRIs are equally effective as first-line agents 1, 5

    • Venlafaxine at 112.5-187.5 mg/day demonstrated significant reductions in panic symptoms 6

Psychotherapy

  • CBT is the psychotherapy of choice 1, 7, 8
    • Should include interoceptive exposure (deliberately inducing panic-like sensations to reduce fear response) 6
    • Standard protocol: 12 weekly sessions 6
    • Can be delivered individually or in group format (6 patients/group) 6

Combined Treatment Superiority

The combination of pharmacotherapy and CBT produces better outcomes than either modality alone 6, 1, 3, 7. This is the most successful treatment strategy for panic disorder. When patients fail to respond adequately to 12 sessions of CBT alone, adding an SSRI produces significantly greater symptom reduction 6.

Alternative and Augmentation Strategies

Second-Line Medications

  • Tricyclic antidepressants (TCAs) are equally effective but less well tolerated than SSRIs 1, 3, 5

    • Imipramine is the most studied TCA
    • Side effect profile limits their use as first-line agents
  • MAOIs can be efficacious but have significant dietary restrictions and drug interactions that preclude first-line use 1, 4

Benzodiazepines: Use With Caution

Benzodiazepines should NOT be first-line treatment despite demonstrating short-term efficacy 1. They are reserved for:

  • Short-term use only (first few weeks while waiting for SSRI/SNRI onset) 4, 5
  • Treatment-resistant cases without history of substance dependence 3, 5
  • Clonazepam at 1.5-3 mg/day can be used as augmentation 6

Critical caveat: The 2025 Brazilian guidelines explicitly state benzodiazepines are not recommended as first-line due to dependency concerns and long-term risks 1.

Treatment-Resistant Cases

When patients fail initial SSRI/SNRI treatment:

  1. Increase the SSRI dose before switching (though one study showed no difference between continuing current dose vs. increasing) 6

  2. Add CBT if not already implemented - 12 weekly sessions of CBT augmentation showed equivalent efficacy to clonazepam augmentation in SSRI non-responders 6

  3. Consider augmentation strategies:

    • Olanzapine 5 mg/day augmentation showed significant improvements from week 2 through week 8 6
    • Clonazepam augmentation (mean 1.5 mg/day) 6
  4. Switch to alternative antidepressant class if no response after adequate trial

Treatment Duration

Continue medications for 6-12 months after remission 5. Relapse is frequent with premature discontinuation, as panic disorder is often chronic 7. Long-term treatment is necessary due to the chronicity of the illness.

What NOT to Do

  • Do not use eye movement desensitization and reprocessing (EMDR) for panic disorder - not recommended by guidelines 8
  • Do not use exposure therapy alone without CBT framework - not recommended 8
  • Do not use benzodiazepines as monotherapy for long-term management 1
  • Do not stop treatment prematurely - minimum 6 months continuation after remission 5

Practical Implementation Algorithm

  1. Initiate SSRI (e.g., sertraline 25-50 mg, titrate to 150-200 mg) OR SNRI (e.g., venlafaxine 75 mg, titrate to 150-225 mg)

  2. Simultaneously refer for CBT with interoceptive exposure component (12 weekly sessions)

  3. Consider short-term benzodiazepine (2-4 weeks) only if severe acute symptoms while awaiting antidepressant onset

  4. Assess response at 6-8 weeks:

    • If inadequate response: increase dose or add CBT if not already implemented
    • If partial response: continue and reassess at 12 weeks
    • If no response: switch antidepressant class or add augmentation
  5. Continue treatment 6-12 months after achieving remission before considering taper

This evidence-based approach prioritizes both immediate symptom control and long-term remission while minimizing risks of dependency and maximizing quality of life outcomes.

References

Research

[Panic disorder: clinical phenomena and treatment options].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2017

Research

Pharmacological treatment of panic disorder.

Modern trends in pharmacopsychiatry, 2013

Research

Management of panic disorder.

Expert review of neurotherapeutics, 2005

Research

Current and Novel Psychopharmacological Drugs for Anxiety Disorders.

Advances in experimental medicine and biology, 2020

Research

The treatment of panic disorder.

Current opinion in psychiatry, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.